Effect of chymase inhibition on the arteriovenous fistula stenosis in dogs

Journal of the American Society of Nephrology

Volumn 16, Issue 4, 2005, Pages 1024-1034

  Jin, Denan ^a   Ueda, Haruhiko ^a   Takai, Shinji ^a   Okamoto, Yukiko ^a   Muramatsu, Michiko ^a   Sakaguchi, Masato ^a   Shibahara, Nobuhisa ^a   Katsuoka, Yoji ^a   Miyazaki, Mizuo ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; CHYMASE; CHYMASE INHIBITOR; LISINOPRIL; N [1 BENZYL 2,3 DIOXO 6 (2 PYRIDYLOXY)HEXYL] 2 (5 FORMYLAMINO 1,6 DIHYDRO 6 OXO 2 PHENYL 1 PYRIMIDINYL)ACETAMIDE; TRANSFORMING GROWTH FACTOR BETA; ACETAMIDE DERIVATIVE; ANGIOTENSIN II; PROTEINASE INHIBITOR; PYRIMIDINE DERIVATIVE; SERINE PROTEINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; BRACHIAL ARTERY; CONTROLLED STUDY; DISEASE SEVERITY; DOG; DRUG EFFECT; ENZYME INHIBITION; INTIMA; KIDNEY ARTERIOVENOUS FISTULA; MAST CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; ARTERIOVENOUS SHUNT; DRUG ANTAGONISM; ENZYMOLOGY; HYPERPLASIA; METABOLISM; PATHOLOGY; STENOSIS, OCCLUSION AND OBSTRUCTION; TUNICA MEDIA; VEIN;

ACETAMIDES; ANGIOTENSIN II; ANIMALS; ARTERIOVENOUS SHUNT, SURGICAL; BRACHIAL ARTERY; CHYMASES; CONSTRICTION, PATHOLOGIC; DOGS; HYPERPLASIA; MAST CELLS; PROTEASE INHIBITORS; PYRIMIDINES; RECEPTOR, ANGIOTENSIN, TYPE 1; SERINE ENDOPEPTIDASES; TRANSFORMING GROWTH FACTOR BETA; TUNICA INTIMA; TUNICA MEDIA; VEINS;

EID: 24344488470     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2003121009     Document Type: Article

References (40)

1. Schwab SJ: Vascular access for hemodialysis. Kidney Int 55: 2078-2090, 1999
2. Reilly CF, Tewksbury DA, Schechter NM, Travis J: Rapid conversion of angiotensin I to angiotensin II by neutrophil and mast cell proteinases. J Biol Chem 257: 8619-8622, 1982
3. Takai S, Jin D, Sakaguchi M, Miyazaki M: Chymase-dependent angiotensin II formation in human vascular tissue. Circulation 100: 654-658, 1999
4. Lindstedt KA, Wang Y, Shiota N, Saarinen J, Hyytiainen M, Kokkonen JO, Keski-Oja J, Kovanen PT: Activation of paracrine TGF-β1 signaling upon stimulation and degranulation of rat serosal mast cells: A novel function for chymase. FASEB J 15: 1377-1388, 2001
5. Takai S, Jin D, Sakaguchi M, Katayama S, Muramatsu M, Sakaguchi M, Matsumura E, Kim S, Miyazaki M: A novel chymase inhibitor, 4-[1-([bis-(4-methyl- phenyl)-methyl]-carbamoyl)3-(2-ethoxy-benzyl)-4-oxo-azetidine-2-yloxy]-benzoic acid (BCEAB), suppressed cardiac fibrosis in cardiomyopathic hamsters. J Pharmacol Exp Ther 305: 17-23, 2003
6. Takai S, Yuda A, Jin D, Nishimoto M, Sakagichi M, Sasaki S, Miyazaki M: Inhibition of chymase reduces vascular proliferation in dog grafted veins. FEBS Lett 467: 141-144, 2000
7. Nishimoto M, Takai S, Kim S, Jin D, Yuda A, Sakaguchi M, Yamada M, Sawada Y, Kondo K, Asada K, Iwao H, Sasaki S, Miyazaki M: Significance of chymase-dependent angiotensin II-forming pathway in the development of vascular proliferation. Circulation 104: 1274-1279, 2001
8. Takai S, Jin D, Nishimoto M, Yuda A, Sakaguchi M, Kamoshita K, Ishida K, Sukenaga Y, Sasaki S, Miyazaki M: Oral administration of a specific chymase inhibitor, NK3201, inhibits vascular proliferation in grafted vein. Life Sci 69: 1725-1732, 2001
9. Shiota N, Okunishi H, Takai S, Mikoshiba I, Sakonjo H, Shibata N, Miyazaki M: Tranilast suppresses vascular chymase expression and neointima formation in balloon-injured dog carotid artery. Circulation 99: 1084-1890, 1999
10. Takai S, Sakonjo H, Fukuda K, Jin D, Sakaguchi M, Kamoshita K, Ishida K, Sukenaga Y, Miyazaki M: A novel chymase inhibitor, 2-(5-formylamino-6-oxo-2- phenyl-1,6-dihydropyrimidine-1-yl)-N-[[,4-dioxo-1-phenyl-7-(2-pyridyloxy)] 2-heptyl]acetamide (NK3201), suppressed intimal hyperplasia after balloon injury. J Pharmacol Exp Ther 304: 841-844, 2003
11. Jin D, Takai S, Yamada M, Sakaguchi M, Kamoshita K, Ishida K, Sukenaga Y, Miyazaki M: Impact of chymase inhibitor on cardiac function and survival after myocardial infarction. Cardiovasc Res 60: 413-420, 2003
12. Moller A, Henz BM, Grutzkau A, Lippert U, Aragane Y, Schwarz T, Kruger-Krasagakes S: Comparative cytokine gene expression: Regulation and release by human mast cells. Immunology 93: 289-295, 1998
13. Back JY, Tefferi A, Pardanani A, Li CY: Immunohistochemical studies of c-kit, transforming growth factor-beta, and basic fibroblast growth factor in mast cell disease. Leuk Res 26: 83-90, 2002
14. Fan PY, Schwab SJ: Vascular access: Concepts for the 1990s. J Am Soc Nephrol 3: 1-11, 1992
15. Besarab A, Sullivan KL, Ross RP, Moritz MJ: Utility of intra-access pressure monitoring in detecting and correcting venous outlet stenoses prior to thrombosis. Kidney Int 47: 1364-1373, 1995
16. Windus DW, Audrain J, Vanderson R, Jendrisak MD, Picus D, Delmez JA: Optimization of high-efficiency hemodialysis by detection and correction of fistula dysfunction. Kidney Int 38: 337-341, 1990
17. Dzau VJ, Gibbons GH, Pratt RE: Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia. Hypertension 18[Suppl]: II100-II105, 1991
18. Rosendorff C: The renin-angiotensin system and vascular hypertrophy. J Am Coll Cardiol 28: 803-812, 1996
19. Daemen MJ, Lombardi DM, Bosman FT, Schwartz SM: Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 68: 450-456, 1991
20. Liu SQ: Focal expression of angiotensin II type 1 receptor and smooth muscle cell proliferation in the neointima of experimental vein grafts: Relation to eddy blood flow. Arterioscler Thromb Vasc Biol 19: 2630-2639, 1999
21. Geisterfer AA, Peach MJ, Owens GK: Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 62: 749-756, 1988
22. Naftilan AJ, Pratt RE, Eldridge CS, Lin HL, Dzau VJ: Angiotensin II induces c-fos expression in smooth muscle via transcriptional control. Hypertension 13[Suppl]: 706-711, 1989
23. Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ: Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest 91: 2268-2274, 1993
24. Kanzaki T, Tamura K, Takahashi K, Saito Y, Akikusa B, Oohashi H, Kasayuki N, Ueda M, Morisaki N: In vivo effect of TGF-beta 1. Enhanced intimal thickening by administration of TGF-beta 1 in rabbit arteries injured with a balloon catheter. Arterioscler Thromb Vasc Biol 15: 1951-1957, 1995
25. Wolf YG, Rasmussen LM, Ruoslahti E: Antibodies against transforming growth factor-beta 1 suppress intimal hyperplasia in a rat model. J Clin Invest 93: 1172-1178, 1994
26. Ikegaya N, Yamamoto T, Takeshita A, Watanabe T, Yonemura K, Miyaji T, Ohishi K, Furuhashi M, Maruyama Y, Hishida A: Elevated erythropoietin receptor and transforming growth factor-β1 expression in stenotic arteriovenous fistulae used for hemodialysis. J Am Soc Nephrol 11: 928-935, 2000
27. Stracke S, Konner K, Kostlin I, Friedl R, Jehle PM, Hombach V, Keller F, Waltenberger J: Increased expression of TGF-β1 and IGF-I in inflammatory stenotic lesions of hemodialysis fistulas. Kidney Int 61: 1011-1019, 2002
28. Taniguchi Y, Yorioka N, Yamashita K, Masaki T, Yamakido M: Transforming growth factor-β1 may be involved in shunt obstruction in patients on chronic hemodialysis. Nephron 81: 102-105, 1999
29. Heine GH, Ulrich C, Sester U, Bester M, Kohler H, Girndt M: Transforming growth factor β1 genotype polymorphisms determine AV fistula patency in hemodialysis patients. Kidney Int 64: 1101-1107, 2003
30. Waltenberger J: Modulation of growth factor action: Implications for the treatment of cardiovascular diseases. Circulation 96: 4083-4094, 1997
31. Border WA, Noble NA: Transforming growth factor beta in tissue fibrosis. N Engl J Med 331: 1286-1292, 1994
32. Battegay EJ, Raines EW, Seifert RA, Bowen-Pope DF, Ross R: TGF-beta induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell 63: 515-524, 1990
33. Brogi E, Wu T, Namiki A, Isner JM: Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation 90: 649-652, 1994
34. Jawien A, Bowen-Pope DF, Lindner V, Schwartz SM, Clowes AW: Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest 89: 507-711, 1992
35. Lindner V, Reidy MA: Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci U S A 88: 3739-3743, 1991
36. Rutherford C, Martin W, Salame M, Carrier M, Anggard E, Ferns G: Substantial inhibition of neo-intimal response to balloon injury in the rat carotid artery using a combination of antibodies to platelet-derived growth factor-BB and basic fibroblast growth factor. Atherosclerosis 130: 45-51, 1997
37. Kofford MW, Schwartz LB, Schechter NM, Yager DR, Diegelmann RF, Graham MF: Cleavage of type I procollagen by human mast cell chymase initiates collagen fibril formation and generates a unique carboxyl-terminal propeptide. J Biol Chem 272: 7127-7131, 1997
38. Tchougounova E, Forsberg E, Angelborg G, Kjellen L, Pejler G: Altered processing of fibronectin in mice lacking heparin. A role for heparin-dependent mast cell chymase in fibronectin degradation. J Biol Chem 276: 3772-3777, 2001
39. Guo C, Ju H, Leung D, Massaeli H, Shi M, Rabinovitch M: A novel vascular smooth muscle chymase is upregulated in hypertensive rats. J Clin Invest 107: 703-715, 2001
40. Huang XR, Chen WY, Truong LD, Lan HY: Chymase is upregulated in diabetic nephropathy: Implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 14: 1738-1747, 2003